Effects of arzoxifene on vertebral fracture incidence and on invasive breast cancer incidence in postmenopausal women with osteoporosis or with low bone density.

Trial Profile

Effects of arzoxifene on vertebral fracture incidence and on invasive breast cancer incidence in postmenopausal women with osteoporosis or with low bone density.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2014

At a glance

  • Drugs Arzoxifene (Primary)
  • Indications Bone resorption; Breast cancer; Postmenopausal osteoporosis; Vertebral fracture
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GENERATIONS
  • Most Recent Events

    • 08 May 2010 Primary endpoint results presented at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
    • 15 Dec 2009 Actual end date (Nov 2009) and actual number of patients (9369) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top